Clinical impact of gender and age at onset on disease trajectory in primary progressive multiple sclerosis patients.

Autor:	Camerlingo S; Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina., Rubinstein F; Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina., Celia Ysrraelit M; Neurology Department, FLENI, Buenos Aires, Argentina., Correale J; Neurology Department, FLENI, Buenos Aires, Argentina., Carnero Contentti E; Neurology Department, Hospital Alemán, Buenos Aires, Argentina., Rojas JI; Centro de Esclerosis Múltiple Buenos Aires (CEMBA), Buenos Aires, Argentina., Patrucco L; Centro de Esclerosis Múltiple Buenos Aires (CEMBA), Buenos Aires, Argentina., Leguizamon FDV; Hospital General de Agudos Dr. Teodoro Alvarez, Buenos Aires, Argentina., Tkachuk V; Neurology Department, Hospital de Clinicas Jose de San Martin, Buenos Aires, Argentina., Fernandez Liguori N; Neurology Department, Hospital Enrique Tornú, Buenos Aires, Argentina., Cristiano E; Centro de Esclerosis Múltiple Buenos Aires (CEMBA), Buenos Aires, Argentina., Mainella C; Neurology Department, Hospital Español, Buenos Aires, Argentina., Zanga G; Neurology Department, Hospital Dr. César Milstein, Buenos Aires, Argentina., Carra A; Neurology Department, Hospital Británico, Buenos Aires, Argentina., Marrodan M; Neurology Department, FLENI, Buenos Aires, Argentina., Martinez AD; Neurology Department, Hospital Británico, Buenos Aires, Argentina., Silva BA; Neurology Department, Hospital Italiano, Buenos Aires, Argentina., Alonso R; Centro Universitario de Esclerosis Múltiple (CUEM), Hospital Ramos Mejía, Buenos Aires, Argentina; Neurology Department, Sanatorio Güemes, Buenos Aires, Argentina.
Jazyk:	angličtina
Zdroj:	Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Mar; Vol. 30 (3), pp. 336-344. Date of Electronic Publication: 2024 Jan 21.
DOI:	10.1177/13524585231219138
Abstrakt:	Background and Objectives: Primary-progressive multiple sclerosis (PPMS) is characterized by gradual neurological deterioration without relapses. This study aimed to investigate the clinical impact of gender and age at disease onset on disease progression and disability accumulation in patients with this disease phenotype. Methods: Secondary data from the RelevarEM registry, a longitudinal database in Argentina, were analyzed. The cohort comprised patients with PPMS who met inclusion criteria. Statistical analysis with multilevel Bayesian robust regression modeling was conducted to assess the associations between gender, age at onset, and Expanded Disability Status Scale (EDSS) score trajectories. Results: We identified 125 patients with a confirmed diagnosis of PPMS encompassing a total of 464 observations. We found no significant differences in EDSS scores after 10 years of disease progression between genders (-0.08; credible interval (CI): -0.60, 0.42). A 20-year difference in age at onset did not show significant differences in EDSS score after 10 years of disease progression (0.281; CI: -0.251, 0.814). Finally, we also did not find any clinically relevant difference between gender EDSS score with a difference of 20 years in age at onset (-0.021; CI: -0.371, 0.319). Conclusion: Biological plausibility of gender and age effects does not correlate with clinical impact measured by EDSS score. Competing Interests: Declaration of Conflicting InterestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu